Core Viewpoint - ZTE Corporation has filed an international patent application for a mobility management method and device, indicating ongoing innovation efforts despite a decrease in patent filings this year [1] Group 1: Patent Application - The patent application is titled "A Method and Device for Perceiving Mobility Management" with application number PCT/CN2025/088624, and it is set to be published internationally on February 5, 2026 [1] - ZTE has announced a total of 153 international patent applications this year, which represents a decrease of 30.14% compared to the same period last year [1] Group 2: Research and Development Investment - In the first half of 2025, ZTE invested 12.665 billion yuan in research and development, showing a slight decrease of 0.48% year-on-year [1]

Group 1 - The core point of the article is that ZTE Corporation (000063) has filed an international patent application for a wireless communication method and device, with the application number PCT/CN2025/083511, published internationally on February 5, 2026 [1] - ZTE has announced a total of 153 international patent applications this year, which represents a decrease of 30.14% compared to the same period last year [1] - In the first half of 2025, ZTE invested 12.665 billion yuan in research and development, showing a slight decrease of 0.48% year-on-year [1]

证券之星消息，根据企查查数据显示中兴通讯（000063）公布了一项国际专利申请，专利名为"通信方 法、电子装置和计算机程序产品"，专利申请号为PCT/CN2025/084782，国际公布日为2026年2月5日。 专利详情如下： 数据来源：企查查 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 图片来源：世界知识产权组织（WIPO） 今年以来中兴通讯已公布的国际专利申请153个，较去年同期减少了30.14%。结合公司2025年中报财务 数据，2025上半年公司在研发方面投入了126.65亿元，同比减0.48%。 ...

图片来源：世界知识产权组织（WIPO） 今年以来中兴通讯已公布的国际专利申请153个，较去年同期减少了30.14%。结合公司2025年中报财务 数据，2025上半年公司在研发方面投入了126.65亿元，同比减0.48%。 数据来源：企查查 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 证券之星消息，根据企查查数据显示中兴通讯（000063）公布了一项国际专利申请，专利名为"数据传 输方法、通信节点及存储介质"，专利申请号为PCT/CN2025/105784，国际公布日为2026年2月5日。 专利详情如下： ...

Core Viewpoint - ZTE Corporation has filed an international patent application for a "cell switching management method, communication device, storage medium, and program product," with the application number PCT/CN2025/082922, published internationally on February 5, 2026 [1] Group 1: Patent Application - The patent application reflects ZTE's ongoing innovation efforts in communication technology [1] - The company has filed a total of 153 international patent applications this year, which is a decrease of 30.14% compared to the same period last year [1] Group 2: R&D Investment - In the first half of 2025, ZTE invested 12.665 billion yuan in research and development, representing a year-on-year decrease of 0.48% [1]

Core Viewpoint - ZTE Corporation has approved an investment of 200 million RMB to subscribe for shares in the Guangdong-Hong Kong-Macao Greater Bay Area Venture Capital Guidance Fund, aiming to support strategic execution and gain investment returns [1][2][37]. Investment Details - ZTE Corporation will act as a limited partner and invest 200 million RMB in the Guangdong-Hong Kong-Macao Greater Bay Area Venture Capital Guidance Fund [8][2]. - The investment was approved during the 20th meeting of the 10th Board of Directors held on February 6, 2026, and does not require shareholder approval as it does not involve related transactions [8][28]. - The fund has a total registered capital of 450.5 billion RMB and focuses on private equity investments, asset management, and investment management [8][28]. Fund Structure and Partners - The fund is structured as a limited partnership and has a maximum duration of 20 years, focusing on sectors supported by national policies such as information technology, biotechnology, and new materials [28][29]. - The general partner and executive partner of the fund is Shenrun Guochuang (Shenzhen) Investment Co., Ltd., which is a joint venture of Shenzhen Innovation Investment Group [9][10]. Fund Management and Decision-Making - The fund will have a decision-making committee responsible for investment decisions, requiring a majority vote for approval [32]. - The fund's profit distribution follows a "return of capital first, then profit sharing" principle, ensuring that all partners receive their initial contributions before any profits are distributed [33]. Impact on ZTE Corporation - The investment is expected to support ZTE's core business strategy and provide access to quality investment opportunities, although it will not be consolidated into ZTE's financial statements [37].

Core Viewpoint - ZTE Corporation plans to invest 200 million RMB as a limited partner in the Guangdong-Hong Kong-Macao Greater Bay Area Venture Capital Guidance Fund, which has a total scale of 50.45 billion RMB [1] Group 1: Investment Details - The fund will be contributed in cash, with partners required to pay in three installments, starting with at least 40% of the subscribed amount in the first installment [1] - The fund focuses on sectors supported by national policies, including new-generation information technology, biotechnology, high-end equipment manufacturing, new materials and new energy, electronic hardware, and frontier materials [1] Group 2: Strategic Implications - ZTE's investment in the fund supports the strategic execution of its core business and aims to secure investment returns through participation in quality industry investment targets [1] - ZTE does not control the fund and will not consolidate it into its financial statements, following the accounting treatment as per the relevant financial instrument standards [1]

据公告所示，该基金将重点关注新一代信息科技、生物技术、高端装备制造、新材料与新能源、电子硬 件、前沿材料等国家政策支持的领域。中兴通讯出资认购粤港澳基金，一方面为公司核心业务的战略执 行提供支持，另一方面通过参与优质产业投资标的的布局，获取投资回报。 中兴通讯(000063.SZ)公告，公司拟作为有限合伙人出资2亿元认购粤港澳大湾区创业投资引导基金合伙 企业(有限合伙)(简称"粤港澳基金")份额，并签署《粤港澳大湾区创业投资引导基金合伙企业(有限合伙) 合伙协议》。 ...

Group 1 - Heng Rui Medicine's HRS-4642 injection has been included in the list of breakthrough therapeutic varieties, aimed at treating advanced or metastatic pancreatic cancer with KRAS G12D mutation in combination with gemcitabine and albumin-bound paclitaxel, with a total R&D investment of approximately 254 million yuan [1] - Fenglong Co. announced a significant stock price increase of 491.97% from December 25, 2025, to February 5, 2026, and may apply for a trading suspension if prices continue to rise abnormally [2] - Aier Eye Hospital clarified that the reported Xiangyang Hengtai Kang is not affiliated with the company, but is a joint venture established by Aier Medical Investment Group and other investors [3] Group 2 - XWANDA's subsidiary reached a settlement with Weir Electric, which is expected to impact the company's net profit attributable to shareholders by 500 million to 800 million yuan in 2025 [4] - Tianzhong Precision Machine received a lawsuit from eight creditors of its former subsidiary, involving a claim of 108 million yuan [5] - Dongtian Micro plans to invest 400 million yuan to establish a global R&D center and manufacturing headquarters in Dongguan, focusing on precision optical components for optical communication [6] Group 3 - Lvtong Technology's industrial fund plans to invest 10 million yuan in Shenghao Optoelectronics, which specializes in testing equipment for optical communication chips [7] - Tiansheng New Materials has been investigated by the China Securities Regulatory Commission for suspected violations of information disclosure laws [8] - Yahui Long has been placed under investigation by the CSRC for suspected information disclosure violations [9] Group 4 - Longyun Co. plans to acquire 58% of Yuheng Film Industry through a share issuance, with the target company's valuation estimated between 450 million and 530 million yuan [10] - Hu Silicon Industry announced that the National Integrated Circuit Industry Investment Fund plans to reduce its stake by up to 3% [11] - Perfect World reported that its actual controller has reduced his stake by 1.70% through various transactions [12] Group 5 - Sanfu Co. announced that its shareholder, Tangshan Yuanheng Technology Co., intends to reduce its stake by up to 3% [13] - Wanshan Expressway plans to invest 5.42 billion yuan in the expansion of the G30 Lianhuo Expressway in Anhui [14] - New Hope reported sales of 1.1218 million pigs in January, generating revenue of 1.628 billion yuan [15]

Company News - Beijing Capital International Airport Co., Ltd. (00694.HK) expects a net loss of approximately RMB 6.0 billion to RMB 7.6 billion in 2025, a year-on-year reduction of about 45.3% to 56.8%, benefiting from the recovery in aviation market demand and enhanced cost control [1] - Times Electric (03898.HK) anticipates total operating revenue of approximately RMB 28.761 billion in 2025, a year-on-year increase of 15.46%, with a net profit of about RMB 4.105 billion, up 10.88% year-on-year [1] - Hong Kong Tong Holdings (00032.HK) issued a profit warning, expecting a year-on-year increase in profit attributable to shareholders to approximately HKD 660 million for the fiscal year 2025 [1] - Datang Environment Industry Group (01272.HK) issued a profit warning, expecting pre-tax profit to rise to approximately RMB 700 million to RMB 710 million in 2025 [1] Power Generation - Datang New Energy (01798.HK) completed power generation of 3.272 million MWh in January, a year-on-year increase of 6.69% [2] - Longyuan Power (00916.HK) achieved power generation of 7.1627 million MWh in January, a year-on-year growth of 12.05%, with wind power generation increasing by 8.11% and solar power generation rising by 42.25% [2] - Jiangshan Holdings (00295.HK) reported total power generation of approximately 18.3 thousand MWh in January, a year-on-year decrease of 22.13% [4] Real Estate - Yuexiu Property (00123.HK) reported contract sales of approximately RMB 4.201 billion in January, a year-on-year decline of about 36.4% [2] - Poly Real Estate (01238.HK) recorded total contract sales of approximately RMB 470 million in January, a year-on-year decrease of 31.98% [2] - Greenland Hong Kong (00337.HK) reported contract sales of approximately RMB 508 million in January, a year-on-year increase of about 287.79% [3] Other Developments - CloudTop New Drug (01952) received approval for the new drug application of Vedolizumab for treating moderate to severe ulcerative colitis in adults in China [4] - Zhonghang Science and Technology (02357.HK) plans to invest RMB 58 million to acquire a 10% stake in Zhonghang Jierui [4] - Kelun-Biotech (06990.HK) received approval for the fourth indication of its core product TROP2ADC for treating 2L+ HR+/HER2- breast cancer [4] Financing and Buyback Activities - Kingsoft Corporation (03888.HK) repurchased approximately 1.1142 million shares for about HKD 29.9994 million, with repurchase prices ranging from HKD 26.8 to HKD 27 [7] - Geely Automobile (00175.HK) repurchased approximately 1.665 million shares for about HKD 27.1612 million, with repurchase prices between HKD 15.94 and HKD 16.44 [7] - October Rice Field (09676.HK) repurchased 780,000 shares for approximately HKD 7.3357 million, with repurchase prices between HKD 9.3 and HKD 9.46 [7] - China Galaxy (06881.HK) completed the issuance of corporate bonds totaling RMB 6 billion [7]